Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

It’s hard to believe now, but in 2002 Wall Street had practically given up on McDonald’s.

Boyar Funds Commentary: Is CVS a Value Trap or a Fallen Angel Ready to Rise Again?

Rite Aid

Which retail drugstore chain is more worthy of your investment dollars?

Better Buy: Rite Aid vs. CVS Health

Curaleaf Holdings, Inc.

GW Pharmaceuticals

The U.S. Food and Drug Administration's harsh stance on cannabidiol should surprise no one.

The FDA Just Showed Its Hand on CBD -- Is It Time for Investors to Fold?

CVS Health stock has been under pressure for a while now. But with CVS stock trading better, is it suddenly worth a buy?

Is CVS Stock a Buy With a 3.5% Dividend and 20% Upside? 

Don't be scared away by near-term uncertainty. CVS stock makes a great long-term bet in the healthcare space if you can stomach some turbulence in the second half of 2019.

A Healthcare Overhaul Makes CVS Stock a Buy Despite Near-Term Uncertainty

AMC Entertainment

Activision Blizzard

Canopy Growth

Foot Locker

Netflix

Tesla

The stock market has surged to all-time highs in 2019. These oversold stocks haven't.

7 Oversold Stocks To Buy Right Now

CVS stock has been a laggard for the past four years.  But the company, of course, keeps trying to get things back on track.

CVS Stock Bears Have Got It All Wrong

Searching for fallen angels is an effective technique for uncovering undervalued stocks. One of the pitfalls of using this method is being caught in a value trap.

Is CVS A Value Trap Or A Fallen Angel Ready To Rise Again?

Massive changes in the health care landscape have brought CVS stock crashing down to earth. However, CVS Health stock is one of the best names in a troubled segment.

Here’s The Not-So-Crazy Speculative Case for CVS Health Stock

Want proof that brick-and-mortar businesses aren't dead? Just look at this company.

How CVS Makes its Money

Over the years, CVS stock has incurred some painful losses in the markets. However, bold moves by management make this a compelling contrarian buy.

The Worst Appears to Be Over for CVS Stock

DaVita

Fresenius Medical Care

CVS Health began a trial of a home dialysis system that could cut into a market controlled by Fresenius Medical and DaVita. But all three stocks fell.

CVS Health Tests Home Dialysis System; DaVita, Fresenius Hit

Long-term shareholders in the retail pharma giant CVS stock are likely to be rewarded handsomely
The post CVS Stock Will Come Back Strong, but Be Wary of Upcoming Earnings appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					2 Toxic Pot Stocks You Should Avoid				
			
					
				
					9 Retail Stocks Goldman Sachs Says Are Ready to Rip				
			
					
				
					7 Services Stocks to Buy for the Rest of 2019				
			
					
				
					6 Stocks to Buy and 1 to Sell Based on Insider Trading

CVS Stock Will Come Back Strong, but Be Wary of Upcoming Earnings

The multi year sell-off in CVS stock may be coming to an end, and what comes next could be a big rally.
The post Right Now It Looks as If It Is Time for CVS Stock to Breakout Higher appeared first on InvestorPlace.

Right Now It Looks as If It Is Time for CVS Stock to Breakout Higher

Shares of the pharmacy chain dipped on a weak outlook for 2019 as it works to integrate the Aetna acquisition.

Why CVS Health Stock Lost 17% Through the First Half of 2019

Brookfield Infrastructure Partners L.P.

Costco

3 Top Dividend Stocks to Buy Right Now: BIP, COST & CVS

Merck

Longstanding cycles in CVS Health and Merck are at risk of changing and offering profits to spread traders buying CVS stock and shorting MRK.
The post A Pairs Prescription for CVS Stock and Merck appeared first on InvestorPlace.

A Pairs Prescription for CVS Stock and Merck

CVS gained cash flow with Aetna. It is now focused on cutting the costs of serving those patients with its HealthHubs.

CVS Stock Is a Buy as It Prepares to Take on Private Insurance

Abercrombie & Fitch

Ascena Retail Group

Bed Bath & Beyond

Chico's FAS

Dollar Tree

FRED'S

Gap Inc

Landbridge Co LLC

Pier 1 Imports

Party City Holdco

Despite the year being more than halfway over, the pace of store closures doesn’t appear to be slowing down in the retail industry. More companies piled on the bad news this week.

Store closures accelerate and may top 12,000 in 2019. Here's what's closed so far this year

Options trading was buzzing in Bed Bath & Beyond, CVS, and Merck on Thursday. Here are the metrics that matter moving forward.

Friday’s Vital Data: Bed Bath & Beyond, CVS and Merck

Bank of America

Delta Air Lines

Goldman Sachs

Kroger

Lennar

United Rentals

Record highs for U.S. stocks are partly the result of rising valuations, but shares of these solid companies have managed to stay cheap.

8 Bargain Blue Chips Hidden Amid Stock Market's Rise To Record

CVS Health rose on news the White House is dropping a plan that could have hurt its profits.

News for CVS Health Stock (CVS)